Diagnosing Alzheimer’s disease involves a combination of cognitive testing, brain imaging, and increasingly, biological tests that detect the disease’s signature proteins in blood or spinal fluid. There is no single test that confirms Alzheimer’s on its own. Instead, doctors build a case by ruling out other causes of memory loss, measuring how well the brain is functioning, and looking for physical evidence of the disease’s underlying biology.
It Starts With Cognitive Testing
The first step in most evaluations is a standardized cognitive exam. Two of the most common are the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE). Both are short, in-office tests that take around 10 to 15 minutes and measure memory, attention, language, and spatial reasoning. On the MoCA, a score of 26 or higher out of 30 is considered normal. On the MMSE, the normal cutoff is 24 or higher out of 30.
These tests are useful for detecting that something is off, but they can’t tell you why. A low score could reflect Alzheimer’s, another form of dementia, depression, medication side effects, or even a vitamin deficiency. That’s why cognitive testing is always paired with further evaluation.
More detailed neuropsychological testing may follow, especially if early-stage disease is suspected. These longer assessments, sometimes lasting a few hours, map out specific patterns of memory loss. Alzheimer’s tends to impair episodic memory first, meaning the ability to form and recall new experiences, and this pattern helps distinguish it from other conditions.
Ruling Out Other Causes
A significant part of the diagnostic process is eliminating conditions that mimic Alzheimer’s. The list is longer than most people expect. Lewy body dementia, frontotemporal dementia, and vascular disease in the brain can all produce memory loss and confusion that look similar to Alzheimer’s on the surface. So can depression, thyroid disorders, vitamin B12 deficiency, obstructive sleep apnea, and even normal-pressure hydrocephalus, a buildup of fluid in the brain that is sometimes treatable with surgery.
Certain medications also impair memory. Benzodiazepines, opioids, some anti-seizure drugs, and anticholinergic medications (found in many over-the-counter sleep aids and allergy drugs) can all cause cognitive symptoms. A thorough medication review is a standard part of the workup. Traumatic brain injury, alcohol use, and past episodes of oxygen deprivation to the brain are also considered. Doctors typically order blood work to check thyroid function, B12 levels, and other metabolic markers before moving to more specialized testing.
Brain Imaging With MRI
Most people undergoing an Alzheimer’s evaluation will get an MRI of the brain. The scan serves two purposes: it can reveal patterns of brain shrinkage consistent with Alzheimer’s, and it can rule out structural problems like tumors, strokes, or fluid buildup.
Radiologists look specifically at the medial temporal lobe, the region that includes the hippocampus, which is critical for forming new memories and is one of the first areas Alzheimer’s damages. They use a visual rating scale called the medial temporal atrophy (MTA) scale to score the degree of shrinkage. What counts as abnormal depends on age. For someone under 70, even mild atrophy (a score of 1 on a 0 to 3 scale) is considered abnormal. For someone over 80, only severe atrophy (a score of 3) is flagged. This age adjustment matters because some brain volume loss is a normal part of aging.
Additional rating scales assess shrinkage in the back of the brain (posterior atrophy) and the frontal lobes. Different patterns of atrophy point toward different types of dementia, which helps narrow the diagnosis.
PET Scans for Amyloid and Tau
PET scans can directly visualize the two hallmark proteins of Alzheimer’s disease: amyloid plaques and tau tangles. These scans involve injecting a small amount of radioactive tracer that binds to one of these proteins, then imaging the brain to see where it accumulates.
Amyloid PET scans are considered appropriate for people who already show signs of mild cognitive impairment or dementia and are suspected of having Alzheimer’s, particularly those under 65 or those with atypical symptoms like unusual behavioral changes or rapid progression. They’re also recommended when spinal fluid test results are inconclusive. For people with no cognitive symptoms, amyloid PET is rarely appropriate, even if they have risk factors like a family history of the disease.
Tau PET scans are newer and play a growing role in prognosis. In someone already diagnosed with mild cognitive impairment due to suspected Alzheimer’s, a tau PET scan can help predict how quickly the disease is likely to progress. The amount and location of tau in the brain correlates more closely with symptom severity than amyloid does.
Spinal Fluid Testing
Cerebrospinal fluid (CSF) analysis, obtained through a lumbar puncture (spinal tap), has been a reliable method for detecting Alzheimer’s biology for years. The test measures levels of amyloid-beta and tau proteins in the fluid that surrounds the brain and spinal cord.
In Alzheimer’s disease, amyloid-beta levels in the spinal fluid drop (because the protein is getting trapped in plaques in the brain rather than circulating normally), while tau levels rise (reflecting damage to brain cells). Doctors look at ratios between these proteins rather than raw numbers, because ratios are more accurate. A positive result on any one of these core biomarker ratios is now considered sufficient to confirm Alzheimer’s biology under the latest diagnostic framework.
Spinal taps are safe but not exactly comfortable. The procedure takes about 20 to 30 minutes, and some people experience a headache afterward that can last a day or two. Despite this, CSF testing remains one of the most definitive ways to confirm or rule out Alzheimer’s pathology, especially when imaging results are unclear.
Blood Tests: A Major Shift
The biggest recent change in Alzheimer’s diagnosis is the arrival of blood-based biomarker tests. In January 2025, the FDA cleared the first blood test for use in diagnosing Alzheimer’s disease. The test measures the ratio of two proteins, a form of tau called p-tau 217 and amyloid-beta, in a standard blood draw.
The accuracy numbers are striking. In clinical studies, 91.7% of people who tested positive on the blood test were confirmed to have amyloid plaques by PET scan or spinal fluid analysis. Among those who tested negative, 97.3% were confirmed negative by those same methods. The test is approved for adults 55 and older who are already showing signs of cognitive decline.
This is not a screening test for the general population, and it’s not meant to be used alone. A positive result still needs to be interpreted alongside cognitive testing, imaging, and clinical history. But it represents a major step toward making biological confirmation of Alzheimer’s accessible outside of specialized research centers, since a blood draw is far simpler and cheaper than a PET scan or spinal tap.
The Neurological Exam
A standard neurological exam is part of every Alzheimer’s evaluation, though its findings in early Alzheimer’s are often unremarkable. The doctor will check reflexes, muscle strength, coordination (using finger-to-nose and heel-to-shin tests), gait, and cranial nerve function. In early stages, these are typically normal, which actually helps distinguish Alzheimer’s from other neurological conditions that cause motor symptoms earlier. As the disease advances, abnormal reflexes, gait problems, and tremor become more common.
Genetic Testing
Genetic testing for Alzheimer’s, specifically for the APOE-e4 gene variant, is not part of routine diagnosis for most people. Carrying one or two copies of APOE-e4 increases risk but does not guarantee the disease, and many people with Alzheimer’s don’t carry the variant at all.
Current guidelines recommend APOE testing only after biomarker testing has already been done, and only for patients who are interested in treatment with newer amyloid-lowering drugs. These medications carry a risk of brain swelling and bleeding that is significantly higher in APOE-e4 carriers, so knowing a patient’s genetic status is important for treatment safety. For people who aren’t pursuing these treatments, the test offers little practical clinical value.
How the Diagnosis Comes Together
No single test gives the answer. A doctor synthesizes results from cognitive testing, medical history, imaging, and biomarker analysis to reach a diagnosis. The 2024 framework from the National Institute on Aging and the Alzheimer’s Association defines Alzheimer’s as a biological disease rather than a purely clinical one. This means the diagnosis is ultimately grounded in evidence of amyloid and tau pathology in the brain, whether detected through blood, spinal fluid, or PET imaging, rather than in symptoms alone. Two people with identical memory complaints could receive different diagnoses depending on what their biomarkers show.
In practice, this means the diagnostic process often unfolds in stages. An initial visit with cognitive testing and blood work might lead to brain imaging, then to biomarker testing if suspicion remains. The timeline varies. Some people get a clear answer within a few weeks; others go through months of evaluation, especially when symptoms are mild or atypical.